B.1.617.3 SARS CoV-2 spike E156G/Δ157-158 mutations contribute to reduced neutralization sensitivity and increased infectivity
T. Mishra, G. Joshi, A. Kumar, R. Dalavi, P. Pandey, S. Shukla, R. K. Mishra, A. Chande
Abstract
SARS CoV-2 variants raise significant concerns due to their ability to cause vaccine breakthrough infections. Here, we sequence-characterized the spike gene, isolated from a breakthrough infection, that corresponded to B.1.617.3 lineage. Delineating the functional impact of spike mutations using reporter pseudoviruses (PV) revealed that N-terminal domain (NTD)-specific E156G/{Delta}157-158 contributed to increased infectivity and reduced sensitivity to ChAdOx1 nCoV-19 vaccine (Covishield)-elicited neutralizing antibodies. A six-nucleotide deletion (467-472) in the spike coding region introduced this change in the NTD. We confirmed the presence of E156G/{Delta}157-158 in the RT-PCR-positive cases concurrently screened, in addition to other circulating spike (S1) mutations like T19R, T95I, L452R, E484Q, and D614G. Notably, E156G/{Delta}157-158 was present in more than 85% of the sequences reported from the USA, UK, and India in August 2021. The spike PV bearing combination of E156G/{Delta}157-158 and L452R further promoted infectivity and conferred immune evasion. Additionally, increased cell-to-cell fusion was observed when spike harbored E156G/{Delta}157-158, L452R, and E484Q, suggesting a combinatorial effect of these mutations. Notwithstanding, the plasma from a recovered individual robustly inhibited mutant spike PV, indicating the increased breadth of neutralization post-recovery. Our data highlights the importance of spike NTD-specific changes in determining infectivity and immune escape of variants.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines
- The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies.
T. Tada, H. Zhou, … N. R. Landau·bioRxiv·May 14, 2021
- The impact of Spike mutations on SARS-CoV-2 neutralization
C. Rees-Spear, L. Muir, … L. E. McCoy·bioRxiv·Jan 15, 2021
- Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern
M. Jongeneelen, K. Kaszas, … B. Brandenburg·bioRxiv·Jul 1, 2021
- SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
X. Shen, H. Tang, … D. Montefiori·bioRxiv·Jan 27, 2021
- Naturally mutated spike proteins of SARS-CoV-2 variants show differential levels of cell entry
S. Ozono, Y. Zhang, … K. Tokunaga·Nature CommunicationsPeer-reviewed·Feb 8, 2021